A market-access analyst opens the Wegovy prescribing information on DailyMed to answer a single question: will a commercial plan cover the drug for a 42-year-old patient with a BMI of 31 and no diabetes but with hypertension and dyslipidemia? The answer is buried in two sections the analyst has to read in the right order — Indications and Usage, where the FDA-approved population is defined, and Limitations of Use, where FDA narrows that population — and it is misread constantly. A prior-authorization denial built on a misread of the indication section is the single most common avoidable failure in specialty-drug access work, and almost every one of those failures traces back to a reader who treated the label as a reference card instead of a structured regulatory document.
This is a reading guide for the FDA prescribing information (PI) as it appears on DailyMed, the National Library of Medicine's public labeling repository, written for market-access, formulary, prior-authorization, and medical-affairs teams. It covers the two-layer structure of a modern US label, the sections an access team reads in order, the distinction between an indication and a limitation of use, and the operational question that runs underneath all of it: which label statement actually anchors a coverage or PA decision, and which DailyMed page is the authoritative one to cite. It is the regulatory companion to the Orange Book TE reading workflow and the FAERS report reading workflow; it is not coverage advice for any specific plan.
What DailyMed actually is: an SPL mirror, not the approval record
DailyMed (dailymed.nlm.nih.gov) is the National Library of Medicine's repository of drug labeling — over 155,000 labeling documents submitted to FDA by manufacturers in Structured Product Labeling (SPL) format, the XML standard that gives every labeling section a machine-readable LOINC code. FDA receives the SPL, and NLM publishes it in a readable web format searchable by trade name, generic name, NDC, or SETID (the unique identifier for a group of similar SPLs). Each SPL links out to RxNorm, Drugs@FDA, and the Orange Book.
Two things about DailyMed catch access teams off guard. First, the SPL on DailyMed is the labeling the manufacturer currently lists as "in use," and FDA explicitly notes that SPL content has not been verified by the agency and may not be identical to the most recent FDA-approved labeling available on Drugs@FDA. When the precise, as-approved wording matters — for a PA citation, a formulary monograph, or a dispute — the authoritative source is the labeling attached to the approval on Drugs@FDA, cross-checked against DailyMed. Second, for section-wide research across many labels at once (every label with a Boxed Warning mentioning a given term, every indication containing "heart failure"), FDA's FDALabel tool does what DailyMed cannot: full-text search confined to a specific labeling section, with MedDRA-term and pharmacologic-class filters, and results that link directly to the SPL, DailyMed, Drugs@FDA, and the Orange Book. DailyMed is for reading one label; FDALabel is for searching across all of them.
The two-layer structure: Highlights and Full Prescribing Information
Since 2006, FDA requires the PI of every human prescription drug to carry two layers. The Highlights of Prescribing Information is a half-page summary at the top, with strict formatting and length limits, containing a boxed-warning summary (if any), recent major changes, indications and usage, dosage and administration, dosage forms and strengths, contraindications, warnings and precautions, adverse reactions, drug interactions, use in specific populations, and a revision date. Every statement in Highlights carries a cross-reference to the full PI — a notation like "(5.1)" pointing to section 5, subsection 1 — and in the electronic SPL those become hyperlinks.
The Full Prescribing Information (FPI) is the numbered, sectioned regulatory text underneath. Highlights is a navigation aid; the FPI is the document of record. The most common reading error is to stop at Highlights — it is a summary written to fit a half page, and it necessarily omits the population definitions, the dosing caveats, and the limitation language that determine coverage. For access work, read the Highlights line, then follow the cross-reference into the FPI before quoting anything.
The sections, in the order an access team reads them
Boxed Warning
The Boxed Warning (LOINC 34066-1), often called a "black box," is reserved for contraindications or warnings about serious adverse reactions that may lead to death or serious injury. It appears at the very top of the PI, bolded and bordered. For access teams, a boxed warning is a formulary signal: it often triggers tier elevation, REMS requirements, risk evaluation in monographs, and sometimes step therapy or specialist-only prescribing. Not every serious risk carries a boxed warning — many sit in Warnings and Precautions — so the distinction between a boxed warning and a section-5 warning matters in how a payer weights the risk.
1 Indications and Usage
Indications and Usage (LOINC 34067-9) defines the FDA-approved uses, each supported by substantial evidence of effectiveness and substantial evidence of safety. This is the section that determines on-label versus off-label, which in turn drives whether a plan will consider the drug covered at all. An indication statement has three parts to read carefully: the condition, the population (adults versus pediatrics, a specific line of therapy, a biomarker or prior-therapy requirement), and the endpoint basis. "Indicated for the treatment of [condition]" is broad; "indicated for [condition] in patients who have received prior [therapy]" is line-restricted and is the language a PA criterion will mirror.
Limitations of Use
Limitations of Use are presented separately from the indication within the Indications and Usage section, and they are the most consequential field for access work that is also the most often skipped. FDA includes a limitation of use when there is reasonable concern or uncertainty about the risk-benefit profile in a particular subgroup or circumstance — for example, that a drug is not recommended in a specific age range, or that evidence is lacking for a particular disease severity. A limitation is distinct from a contraindication (which forbids use) and from a Warning and Precaution (which cautions about risk during use); it narrows the indication itself. Payers convert limitations into PA criteria directly: if the label says the drug is not indicated for a population, the PA will require documentation that the patient is not in that population. Read the limitation before assuming the indication covers your patient.
2 Dosage and Administration
Dosage and Administration (LOINC 34068-7) defines the recommended dose, the titration schedule, the route, and any pre-treatment requirements (testing, monitoring, premedication). For access teams, this section is the basis for quantity limits, the titration logic in step-therapy programs, and the dosing range a pharmacy benefit manager will authorize. A label that specifies a weekly titration schedule supports a quantity-limit appeal built on the titration calendar; a label that requires baseline labs supports a PA criterion requiring those labs.
4 Contraindications and 5 Warnings and Precautions
Contraindications define circumstances in which the risk clearly outweighs benefit and the drug must not be used; Warnings and Precautions describe clinically significant risks that require monitoring or mitigation. These sections are where the operational risk-management layer lives — the monitoring requirements, the REMS references, the discontinuation rules — and they are the section most often cited in payer risk assessments and in label-change monitoring. When FDA adds a warning post-approval (as it did for GLP-1 receptor agonists with gastroparesis, ileus, and acute kidney injury language in October 2025 and a pulmonary aspiration warning in November 2024), it lands here and in the Boxed Warning if the risk warrants it.
6 Adverse Reactions
Adverse Reactions reports the adverse-event rates observed in the pivotal trials that supported approval, typically in a table of treatment-emergent adverse events by frequency. This is trial-derived incidence, not real-world postmarket reporting — a different evidence type from the spontaneous reports in FAERS. Access teams use section 6 to characterize the expected tolerability burden and to distinguish on-label, expected adverse events from the postmarket signals that drive label changes.
8 Use in Specific Populations
Use in Specific Populations covers pregnancy (LOINC 42228-7), lactation (LOINC 77290-5), reproductive potential, pediatric use, geriatric use, and renal or hepatic impairment. This section drives subpopulation-specific PA criteria — renal-adjusted dosing requirements, pregnancy exclusion criteria, age restrictions — and is the field to read when a PA denial turns on a comorbidity or a life-stage exclusion.
What the label can defensibly anchor for an access team
The label is the single most authoritative statement of FDA's view of a drug's approved use, and for access work it anchors a defined set of decisions.
It anchors on-label versus off-label scope — the Indications and Usage section, read with Limitations of Use, defines what FDA has approved, and plans use that scope as the default boundary of coverage. It anchors PA and step-therapy criteria that are required to be consistent with FDA-approved labeling, including line-of-therapy requirements, prior-therapy requirements, dosing, and monitoring. It anchors formulary risk classification through the Boxed Warning and Warnings and Precautions sections. And it anchors the timeline of post-approval change through the Highlights revision date and the "Recent Major Changes" list, which tells you when FDA last required labeling to be updated.
What the label cannot tell you
The label cannot tell you whether a specific plan will cover the drug — coverage policy is set by the payer, often more narrowly than the label, and may require step therapy, preferred-agent sequencing, or indications the plan does not recognize even when FDA does. It cannot tell you comparative effectiveness against alternatives; FDA labeling is not a head-to-head evidence document, and absence of a competitor's name in a label is not evidence of inferiority. It cannot tell you off-label evidence strength; off-label use is unapproved by definition, and the existence of a published study supporting an off-label use does not put that use on-label. And the SPL on DailyMed cannot be assumed identical to the FDA-approved labeling — for any disputed citation, confirm against Drugs@FDA.
The reading workflow, before citing a label in a PA
Run a label through this sequence before any access submission.
- Pull the authoritative version. Open the label on DailyMed; for a disputed citation, cross-check the approval labeling on Drugs@FDA and confirm the SPL revision date is current.
- Read Highlights, then follow the cross-references into the FPI. Do not quote from Highlights for any criterion that turns on population or dosing detail.
- Isolate the Indications and Usage population. Note the condition, the line of therapy, the biomarker or prior-therapy requirement, and the approved age range.
- Read the Limitations of Use before the indication. Confirm the patient is not in a limited population; if they are, the indication does not extend to them even if the condition matches.
- Map Dosage and Administration to the quantity and titration you are requesting. A PA quantity limit that does not match the labeled titration schedule is appealable.
- Check Warnings and Precautions and the Boxed Warning for monitoring or REMS requirements the PA may require you to document.
- Confirm the payer's criteria match the label, not a narrower interpretation. Where a PA criterion is narrower than the label, the label is the basis for an appeal; where the criterion tracks the label, the label confirms the denial basis.
- Note the revision date and Recent Major Changes. A label recently updated for a safety signal changes the risk conversation with the plan.
DailyMed, Drugs@FDA, FDALabel, and the Orange Book — which source when
The four FDA labeling and registration sources answer different questions, and citing the wrong one is a common error. DailyMed is for reading one current label in full. Drugs@FDA is for the approval record — the as-approved labeling, approval letters, review documents, and approval history that anchor a disputed citation. FDALabel is for section-wide or term-wide searches across all labels at once, including MedDRA-term and pharmacologic-class filters. The Orange Book is for therapeutic equivalence, patent, and exclusivity — whether a generic is rated equivalent and when competition can enter — not for label content. For indication scope and PA documentation, start at DailyMed, confirm at Drugs@FDA, and reserve FDALabel for cross-label research.
What access teams should take from a label
A drug label is a regulatory document with a fixed structure, and competent access work depends on reading that structure rather than scanning it for a keyword. The Indications and Usage section, read together with Limitations of Use, defines the on-label scope that a plan will use as the default coverage boundary. The Boxed Warning and Warnings and Precautions sections define the risk profile the plan weighs in formulary and PA design. The Dosage and Administration section defines the dosing and titration that quantity limits and step therapy must respect. And the authoritative version — DailyMed cross-checked against Drugs@FDA, with the revision date recorded — is what a defensible PA citation actually points to. Read the label the way FDA wrote it: section by section, Highlights as an index, Limitations of Use before the indication, and the approval record as the final word on wording.
Sources
- US FDA, "Frequently Asked Questions about Labeling for Prescription Medicines" (PI section structure, Boxed Warning, Indications and Usage, DailyMed vs Drugs@FDA). https://www.fda.gov/drugs/fdas-labeling-resources-human-prescription-drugs/frequently-asked-questions-about-labeling-prescription-medicines
- US FDA, "Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products — Content and Format" (definition of Limitations of Use and distinction from indication). https://www.fda.gov/files/drugs/published/Indications-and-Usage-Section-of-Labeling-for-Human-Prescription-Drug-and-Biological-Products-%E2%80%94-Content-and-Format-Guidance-for-Industry.pdf
- US National Library of Medicine, DailyMed. https://dailymed.nlm.nih.gov/
- US FDA, "FDALabel: Full-Text Search of Drug Product Labeling" (section-confined search, MedDRA-term and pharmacologic-class filters). https://www.fda.gov/science-research/bioinformatics-tools/fdalabel-full-text-search-drug-product-labeling
- US FDA, Drugs@FDA: FDA-Approved Drugs (approval labeling, approval letters, review documents). https://www.accessdata.fda.gov/scripts/cder/daf/
- IntuitionLabs, "USPI Highlights: A Guide to FDA Drug Labeling Requirements" (Highlights structure, cross-references, SPL/XML, FDALabel, AskFDALabel). https://intuitionlabs.ai/articles/uspi-highlights-fda-labeling-guide
- National Library of Medicine, "Health Data Standards and Terminologies: A Tutorial" (DailyMed, SPL, NDC, SETID, RxNorm). https://www.nlm.nih.gov/oet/ed/healthdatastandards/02-630.html
- Fang et al., "Information Extraction From FDA Drug Labeling to Enhance Product-Specific Guidance Assessment Using Natural Language Processing" (DailyMed/Drugs@FDA section coverage, LOINC labeling codes), Frontiers in Research Metrics and Analytics, 2021. https://www.frontiersin.org/journals/research-metrics-and-analytics/articles/10.3389/frma.2021.670006/full
